Edsel Holden, MD
Pulmonary Disease · Florence, ALNPI 1013015254
Payments from drug & device makers
Across 423 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Olympus Corporation Of The Americas$914
- AstraZeneca$908
- Sanofi$694
- Insmed, Inc.$598
- plus $3K from 30 others
What the payments were for
- Travel & lodging$8699%
- Food & beverage$8,52188%
- Education$3013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 142 | $2,039 |
| Regeneron Healthcare Solutions, Inc. | 49 | $1,185 |
| Olympus Corporation Of The Americas | 8 | $914 |
| AstraZeneca | 41 | $908 |
| Sanofi | 26 | $694 |
| Insmed, Inc. | 25 | $598 |
| Boehringer Ingelheim | 30 | $590 |
| Inspire Medical Systems, Inc. | 6 | $517 |
| Merck | 16 | $317 |
| Astellas Pharma US Inc | 7 | $248 |
| United Therapeutics Corporation | 10 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $213 |
| Lilly USA, LLC | 8 | $137 |
| Genentech USA, Inc. | 6 | $124 |
| Medtronic | 2 | $90 |
| Mylan Specialty L.p. | 5 | $89 |
| Verona Pharma, Inc. | 3 | $81 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Novartis | 4 | $79 |
| Baxter Healthcare | 3 | $68 |
| Jazz Pharmaceuticals Inc. | 3 | $67 |
| Intuitive Surgical | 1 | $56 |
| Harmony Biosciences LLC | 2 | $52 |
| Pulmonx Corporation | 2 | $47 |
| Philips North America LLC | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Vifor Pharma, Inc. | 1 | $29 |
| Mayne Pharma Commercial LLC | 1 | $26 |
| Itamar Medical Inc | 1 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Noah Medical Corporation | 1 | $20 |
| Amgen | 1 | $20 |
| Inogen, Inc. | 2 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Resmed Corp | 1 | $15 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,692 in reported general payments places this provider in the 70th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 871 | $778,338 |
| OfevNintedanib Esylate | 68 | $770,394 |
| Dupixent PenDupilumab | 183 | $708,556 |
| Tyvaso DpiTreprostinil | 28 | $680,219 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 453 | $374,968 |
| NucalaMepolizumab | 71 | $281,929 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 23 | $250,124 |
| Pirfenidone | 68 | $164,418 |
| Spiriva RespimatTiotropium Bromide | 96 | $56,578 |
| SymbicortBudesonide/Formoterol Fumarate | 156 | $51,305 |
| Breo ElliptaFluticasone/Vilanterol | 101 | $44,441 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,159 | $35,448 |
| Advair HfaFluticasone Propion/Salmeterol | 95 | $34,118 |
| XolairOmalizumab | 13 | $30,374 |
| Arnuity ElliptaFluticasone Furoate | 110 | $29,741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $2,039 | $1,180,0771,232 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $590 | $862,746221 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $908 | $443,011641 claims |
| PfizerEliquis | $11 | $29,69633 claims |
| MerckDulera | $317 | $25,14269 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $35 | $5,96319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Florence
- Robert GarverAndalusia$4.6M
- Allan SeibertMobile$2.4M
- Tejaswini KulkarniBirmingham$1.7M
- Jan WestermanJasper$834K
- Bryan GarciaBirmingham$606K
- A RidgewaySheffield$434K
- Darryle BullardCullman$380K
- Marvin SextonDothan$346K
- Veena AntonyBirmingham$327K
- William SaliskiMontgomery$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.